Bristol-Myers Squibb has claimed FDA approval for a new, tumour-agnostic indication for Augtyro, the cancer drug it acquired as part of its $4.1 billion takeover of Turning Point Therapeutics in 2022.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results